



INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401, Fax: 0120-2783311

e-mail: pvpi.ipc@gov.in, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2018-19/02

28th February 2018

Drug Safety Alerts

The preliminary analysis of ADRs from the PvPI database reveals that the following drugs may be associated with the risks as given below.

Table

Sl. No	Suspected Drug	Indication	Adverse Reaction
1	Dapsone	For treatment of leprosy; acne vulgaris, dermatitis, pneumocystic pneumonia	Erythema nodosum

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events associated with the use of above drugs. If such events are encountered please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. **1800-180-3024**.